Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

FACILITATE

- PMLiVE

AstraZeneca’s Tagrisso shows eight-year landmark survival in early-stage EGFR-mutated lung cancer

The results from a global phase 3 trial show the longest survival data ever reported in this setting

- PMLiVE

Almirall’s paediatric registration of Ebglyss for atopic dermatitis gets EMA acceptance

Atopic dermatitis affects a significant number of children and adolescents and often peaks in childhood

- PMLiVE

Pfizer announces phase 3 results for potential non-small cell lung cancer treatment

Patients who had received only one prior line of systemic therapy showed a stronger trend for overall survival and progression-free survival

- PMLiVE

Almirall celebrates new offices in China to advance innovation in dermatology

The company’s R&D and commercial expertise represent valuable capabilities for future Chinese partners

- PMLiVE

Almirall and Absci expand AI dermatological drug discovery partnership

The alliance has already led to the delivery of functional antibody leads against a difficult-to-drug target

- PMLiVE

Almirall hosts Skin Academy to advance skin science and dermatology treatments

The conference will cover actinic keratosis, psoriasis, atopic dermatitis and other skin diseases

- PMLiVE

Eli Lilly/Almirall share positive long-term results for Ebglyss in atopic dermatitis

The inflammatory skin condition occurs in approximately 7.3% of adults in the US

- PMLiVE

Almirall announces NICE recommendation for Ebglyss in atopic dermatitis

The inflammatory skin condition affects about 5.2 million adults and 2.5 million children in the UK

- PMLiVE

Almirall’s Ilumetri shown to improve and maintain well-being in plaque psoriasis patients

Nearly 77% of psoriasis patients report that the condition negatively affects their well-being

- PMLiVE

Almirall’s Klisyri receives expanded FDA approval to treat actinic keratosis

The precancerous condition is responsible for an estimated 60% of all squamous cell carcinoma cases

- PMLiVE

Almirall survey reveals limited knowledge of most common precancerous skin condition

An estimated 60% of squamous cell carcinoma cases, the second most common skin cancer, develop from AK lesions

- PMLiVE

Almirall gains rights to Eloxx’s rare dermatological disease asset in deal worth over $470m

ZKN-013 is designed to overcome nonsense mutations in rare skin diseases such as junctional epidermolysis bullosa

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links